



For Immediate Release

Granville Laboratory Receives Inaugural Michael Smith Foundation for Health Research Innovation to Commercialization (I2C) Award

Vancouver, British Columbia, Canada, August 28, 2017 -- viDA Therapeutics, Inc. (viDA) announced today that Dr. David Granville's laboratory has been awarded a commercialization grant from the Michael Smith Foundation for Health Research (MSFHR) for the development of VTI-1002 topical gel for inflammatory skin diseases with the lead indication being discoid lupus erythematosus (DLE). (www.msfhr.org/novel-therapeutic-inflammatory-skin-diseases)

The I2C Program is designed to help researchers advance discoveries or inventions towards commercialization by supporting commercialization activities that strengthen the value of their intellectual property, facilitate collaboration and attract future investment.

The two year funding from MSFHR will allow for the continued development of VTI-1002 topical gel for skin applications. It provides for further improvements and characterization of the Drug Product as we move the dermatology program towards the clinic for the treatment of the orphan autoimmune skin disease, DLE.

The funding also enables us to push forward into expanding the potential of VTI-1002 gel in other skin indications.

About The Michael Smith Foundation for Health Research (MSFHR)

MSFHR empowers British Columbia's best and brightest health researchers to pursue world-class innovation and stretch the bounds of what health research can achieve.

Since its inception in 2001 by the BC government, MSFHR has received approximately \$450 million from the provincial government to bolster BC's capacity to develop new treatments and cures; help BC's health system be more effective and responsive to emerging health threats; and keep BC's health research sector globally competitive. (www.msfhr.org)

About viDA, Discoid Lupus Erythematosus (DLE) and VTI-1002

viDA Therapeutics, Inc. (viDA), a Vancouver, Canada based privately held biotechnology company, is focused on developing first-in-class therapies for treating autoimmune and chronic inflammatory diseases with high unmet need, including orphan products. The lead product candidate, VTI-1002, is in a topical formulation for the treatment of the autoimmune skin condition, DLE. This disease is a severe chronic dermatological disease having a significant impact on quality of life due to severe facial disfigurement and scars. (www.vidatherapeutics.com)

Media Contact: Alistair Duncan, B.Sc., C.A.
President & CEO
Phone: (604)762-4789
aduncan@vidatherapeutics.com